Skip to main content

Table 1 Patient baseline and disease characteristics of Kaiser Permanente Northern California Cohort (KPNC) Stage I–III breast cancers, diagnosed 2000–2010

From: Modeling risks of cardiovascular and cancer mortality following a diagnosis of loco-regional breast cancer

  All patients
(N = 20,462)
N (%)
Breast Cancer
Death
(N = 842)
CVD
Death
(N = 696)
Age (years)
21–34 302 (1.5%) 13 (1.5%) 3 (0.4%)
35–39 571 (2.8%) 36 (4.3%) 8 (1.2%)
40–44 1340 (6.6%) 65 (7.7%) 12 (1.7%)
45–49 2167 (10.6%) 81 (9.6%) 21 (3.0%)
50–54 2604 (12.7%) 90 (10.7%) 33 (4.7%)
55–59 2962 (14.5%) 104 (12.4%) 39 (5.6%)
60–64 2866 (14.0%) 106 (12.6%) 52 (7.5%)
65–69 2482 (12.1%) 78 (9.3%) 71 (10.2%)
70–74 2004 (9.8%) 81 (9.6%) 109 (15.7%)
75 +  3164 (15.5%) 188 (22.3%) 348 (50.0%)
Race
Non-Hispanic White 14,181 (69.3%) 601 (71.4%) 531 (76.3%)
Hispanic White 1985 (9.7%) 77 (9.1%) 38 (5.5%)
Non-Hispanic Black 1500 (7.3%) 81(9.6%) 85 (12.2%)
Hispanic Black 7 (< 0.1%) 0 0
Asian/Pacific Islander 2719 (13.3%) 80 (9.5%) 40 (5.8%)
Other/Unknown 70 (0.3%) 3 (0.4%) 2 (0.2%)
Smoking status at diagnosis
Current smoker 2430 (11.9%) 109 (13.0%) 126 (18.1%)
Former smoker 3095 (24.0%) 100 (11.9%) 97 (13.9%)
Non-smoker 7389 (36.1%) 162 (19.2%) 97 (13.9%)
Unknown 7548 (36.9%) 471 (55.9%) 376 (54.0%)
Diabetes 2669 (13.1%) 104 (12.4%) 160 (23.0%)
Charlson comorbidity
0 13,130 (64.2%) 544 (64.6%) 277 (39.8%)
1–2 6137 (30.0%) 240 (28.5%) 288 (41.4%)
3 +  1163 (5.7%) 56 (6.7%) 130 (18.7%)
unknown 32 (0.2%) 2 (0.2%) 1 (0.1%)
Breast Cancer Characteristics
Bilateral
Unilateral—Right
Unilateral-Left
Unilateral—Unknown
138 (0.7%)
9842 (48.1%)
10,476 (51.2%)
6 (< .01%)
4 (0.5%) 8 (1.2%)
Surgery
None 560 (2.7%) 59 (7.0%) 39 (5.6%)
Lumpectomy 11,583 (56.6%) 270 (32.1%) 321 (46.1%)
Mastectomy 8309 (40.6%) 512 (60.8%) 334 (48.0%)
Unknown 10 (0.1%) 1 (0.1%) 2 (0.3%)
Grade
1 Well differentiated 4734 (23.1%) 37 (4.4%) 130 (18.7%)
2 Moderately differentiated 8336 (40.7%) 287 (34.1%) 272 (39.1%)
3 Poorly differentiated 5481(26.8%) 424 (50.4%) 198 (28.5%)
4 Diffuse 259 (1.3%) 20 (2.4%) 7 (1.0%)
Unknown 1652 (8.1%) 74 (8.8%) 89 (12.8%)
Stage
1 10,843 (53.0%) 127 (15.1%) 294 (42.3%)
2 7806 (38.2%) 444 (52.7%) 316 (45.4%)
3 1813 (8.9%) 271 (32.2%) 86 (12.4%)
Tumor size
 ≤ 2 cm 13,727 (67.1%) 269 (32.0%) 393 (56.5%)
(2,5] cm 5723 (28.0%) 411 (48.8%) 244 (35.1%)
 > 5 cm 838 (4.1%) 117 (13.9%) 44 (6.3%)
Diffuse or Unknown 174 (0.9%) 45 (5.3%) 15 (2.2%)
ER/PR
Positive 11,917 (58.2%) 393 (46.7%) 442 (63.5%)
Negative 2689 (13.1%) 253 (30.1%) 105 (15.1%)
Unknown/not done 5856 (28.6%) 196 (23.3%) 149 (21.4%)
HER2
Positive 1862 (9.1%) 110 (13.1%) 49 (7.0%)
Negative 11,938 (58.3%) 422 (50.1%) 417 (59.9%)
Unknown/not done 6662 (32.6%) 310 (36.8%) 230 (33.1%)
Positive Lymph Nodes
0 14,150 (69.2%) 327 (71.1%) 449 (64.5%)
1–3 4429 (21.7%) 234 (21.3%) 156 (22.4%)
 > 3 1851 (9.1%) 279 (7.5%) 87 (12.5%)
None examined/unknown 32 (0.2%) 2 (0.1%) 4 (0.6%)
Treatments received
Any chemotherapy 9639 (47.1%) 596 (70.8%) 204 (29.3%)
Taxanes 2806 (13.7%) 220 (26.1%) 47 (6.8%)
Targeted Therapy 1206 (5.9%) 78 (9.3%) 16 (2.3%)
Alkylating Agents 1626 (8.0%) 113 (13.4%) 41 (5.9%)
Antimetabolites 1061 (5.2%) 174 (20.7%) 33 (4.7%)
Vinca Alkaloids 364 (1.8%) 94 (11.2%) 14 (2.0%)
Other 1174 (5.7%) 133 (15.8%) 23 (3.3%)
No Chemotherapy 10,823 (52.9%) 246 (29.2%) 492 (70.7%)
Any hormonal therapy 8463 (41.4%) 265 (31.5%) 282 (40.5%)
Any radiation 6621(32.4%) 247(29.3%) 184 (26.4%)